StartNTLA • NASDAQ
add
Intellia Therapeutics Inc
Seneste lukkekurs
12,02 $
Dagsinterval
9,93 $ - 11,43 $
Årsinterval
9,93 $ - 34,87 $
Markedsværdi
1,04 mia. USD
Gns. volumen
2,36 mio.
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (USD) | sep. 2024info | År til år-ændring |
|---|---|---|
Indtægt | 9,11 mio. | -24,02 % |
Driftsudgifter | 30,50 mio. | 3,73 % |
Nettoindtægt | -135,71 mio. | -11,04 % |
Overskudsgrad | -1,49 t | -46,15 % |
Earnings per share | -1,34 | 2,90 % |
EBITDA | -142,16 mio. | -10,36 % |
Effektiv afgiftssats | — | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (USD) | sep. 2024info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 658,11 mio. | -23,01 % |
Samlede aktiver | 1,17 mia. | -5,63 % |
Samlede passiver | 210,74 mio. | 2,33 % |
Samlet egenkapital | 962,62 mio. | — |
Shares outstanding | 101,85 mio. | — |
Kurs/indre værdi | 1,27 | — |
Afkast af aktiver | -30,61 % | — |
Afkast af kapital | -33,80 % | — |
Pengestrøm
Nettoændring i likviditet
| (USD) | sep. 2024info | År til år-ændring |
|---|---|---|
Nettoindtægt | -135,71 mio. | -11,04 % |
Pengestrøm fra drift | -84,84 mio. | 16,32 % |
Pengestrøm fra investering | -7,71 mio. | -109,70 % |
Pengestrøm fra finansiering | 82,19 mio. | 330,28 % |
Nettoændring i likviditet | -10,35 mio. | -272,58 % |
Fri pengestrøm | -35,80 mio. | 44,08 % |
Om
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Administrerende direktør
Grundlagt
2014
Hovedkvarter
Website
Ansatte
526
